Retatrutide vs semaglutide vs tirzepatide (US): differences, effectiveness, and side effects

TL;DR (plain-English summary)

Semaglutide and tirzepatide are available in the U.S. as FDA-approved prescription medications (brand names vary by indication).
Retatrutide is not FDA-approved as of this writing; it’s an investigational once-weekly injection being studied in clinical trials.
How they work:
- Semaglutide targets GLP‑1.
- Tirzepatide targets GIP + GLP‑1.
- Retatrutide targets GIP + GLP‑1 + glucagon (a “triple agonist”).
Average weight-loss results in major trials (not a promise for any individual):
- Semaglutide 2.4 mg in STEP 1: ~14.9% at 68 weeks (adults without diabetes).
- Tirzepatide in SURMOUNT-1: ~15.0% to 20.9% at 72 weeks depending on dose (adults without diabetes).
- Retatrutide phase 2 trial: up to ~24.2% at 48 weeks in a studied dose group (adults with obesity/overweight).
Side effects overlap a lot: nausea, diarrhea, constipation, vomiting, abdominal pain, reflux/indigestion—often worst during dose increases.
Safety and practicality often decide “best”: FDA approval/insurance, contraindications (e.g., MTC/MEN2 warnings for approved GLP‑1–based drugs), pregnancy plans, kidney/gallbladder history, and how well you tolerate GI effects.

Educational only, not medical advice. Discuss risks/benefits and alternatives with a licensed clinician who knows your history.

Quick comparison (website table)

Feature	Retatrutide	Semaglutide	Tirzepatide
U.S. status	Investigational (not FDA-approved)	FDA-approved (brands vary by indication)	FDA-approved (brands vary by indication)
Receptors targeted	GIP + GLP‑1 + glucagon	GLP‑1	GIP + GLP‑1
Typical dosing	Once weekly injection in trials (dose escalation studied)	Once weekly injection (dose escalation; Wegovy maintenance 2.4 mg)	Once weekly injection (dose escalation; multiple maintenance doses)
Trial weight-loss magnitude (adults without diabetes; averages)	Up to ~24% at 48 weeks (phase 2)	~15% at 68 weeks (STEP 1)	~15–21% at 72 weeks (SURMOUNT-1)
Common side effects	GI (nausea/diarrhea/constipation/vomiting), may include heart-rate increase	GI (nausea/diarrhea/constipation/vomiting)	GI (nausea/diarrhea/constipation/vomiting)
Key “real-life” issue	Not available by prescription outside trials	Coverage + availability + tolerability	Coverage + availability + tolerability

WhatsApp-friendly “table” (same info as bullets)

U.S. status
- Retatrutide: investigational (not FDA-approved)
- Semaglutide: FDA-approved (brands vary by indication)
- Tirzepatide: FDA-approved (brands vary by indication)
What they target
- Retatrutide: GIP + GLP‑1 + glucagon
- Semaglutide: GLP‑1
- Tirzepatide: GIP + GLP‑1
How often (typical)
- All three: once-weekly injections (retatrutide only in trials)
Average trial weight loss (context-dependent)
- Retatrutide: up to ~24% at 48 weeks (phase 2)
- Semaglutide 2.4 mg: ~15% at 68 weeks (STEP 1)
- Tirzepatide: ~15–21% at 72 weeks (SURMOUNT-1)
Common side effects
- Overlap across all: nausea, diarrhea, constipation, vomiting, abdominal pain, indigestion/reflux
Big practical difference
- Retatrutide: not available outside clinical trials
- Semaglutide/tirzepatide: access depends on insurance, cost, stock, and tolerability

First, clarify the “names” (brands vs molecules)

Patients often compare molecule names, but prescriptions are usually written for a brand tied to an FDA indication.

Semaglutide (GLP‑1 receptor agonist)

In the U.S., semaglutide is marketed as:

Wegovy® — FDA-approved for chronic weight management (semaglutide 2.4 mg)
Ozempic® — FDA-approved for type 2 diabetes (and cardiovascular risk reduction in certain adults with type 2 diabetes)
Rybelsus® — oral semaglutide for type 2 diabetes

Internal link: Ozempic vs Wegovy

Tirzepatide (dual GIP/GLP‑1 receptor agonist)

In the U.S., tirzepatide is marketed as:

Zepbound® — FDA-approved for chronic weight management
Mounjaro® — FDA-approved for type 2 diabetes

Internal link: Mounjaro vs Zepbound

Retatrutide (triple agonist: GIP/GLP‑1/glucagon)

Retatrutide (LY3437943) is an investigational medication studied as a once-weekly injection in clinical trials.

It is not FDA-approved for weight loss or diabetes as of this writing.
You generally can’t get it legally from a U.S. retail pharmacy.

Internal links (placeholders):

How they work (patient-friendly science)

All three medications influence appetite and metabolism through “incretin” (and related) hormone pathways. That often leads to:

reduced hunger
earlier fullness
fewer cravings for some people
improved blood sugar regulation (especially relevant if you have diabetes)

Semaglutide: GLP‑1

GLP‑1 (glucagon-like peptide‑1) is a hormone released after meals. GLP‑1 medicines can:

increase fullness
slow stomach emptying (often more noticeable early in treatment)
reduce appetite

Tirzepatide: GIP + GLP‑1

Tirzepatide activates:

GLP‑1 pathways (similar category benefits)
GIP (glucose-dependent insulinotropic polypeptide) pathways

Researchers believe the dual activity helps explain why tirzepatide produces greater average weight loss than GLP‑1 alone in many trials.

Retatrutide: GIP + GLP‑1 + glucagon

Retatrutide adds glucagon receptor agonism on top of GIP/GLP‑1.

In simple terms, the “triple” approach aims to influence appetite and energy balance through multiple hormonal signals.
This may improve average weight-loss outcomes in research—but it may also come with different side-effect patterns (for example, changes in heart rate were observed in the phase 2 trial).

Effectiveness: what the best-known studies show (and how to interpret them)

A crucial caution: trials aren’t perfectly comparable

It’s tempting to line up percentages and pick the biggest number, but trials differ by:

how long they ran (48 vs 68 vs 72 weeks)
who was included (with or without diabetes, different baseline weights)
dosing strategies and escalation schedules
lifestyle programs provided in the trial

The best way to use trial results is as a ballpark expectation, not a personal prediction.

Semaglutide 2.4 mg (STEP 1; adults without diabetes)

In STEP 1, adults with overweight/obesity without diabetes had:

~14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg
vs ~2.4% with placebo

Why it matters: this trial is a key reason Wegovy is considered an effective, evidence-based option for chronic weight management.

Tirzepatide (SURMOUNT-1; adults without diabetes)

In SURMOUNT-1, adults with overweight/obesity without diabetes had (depending on dose):

~15.0% mean weight loss at 72 weeks (5 mg)
~19.5% mean weight loss at 72 weeks (10 mg)
~20.9% mean weight loss at 72 weeks (15 mg)
vs ~3.1% with placebo

Why it matters: tirzepatide produced very large average reductions and is often viewed as a “higher potency on average” option—if you can access and tolerate it.

Retatrutide (phase 2; adults with obesity/overweight)

In the phase 2 trial published in NEJM, at 48 weeks, studied groups had (least-squares mean changes):

up to ~24.2% mean weight loss in a retatrutide dose group
vs ~2.1% with placebo

Important: this is phase 2 research.

Phase 2 trials help estimate dosing and side effects, but phase 3 trials are the usual basis for FDA approval decisions.
Until FDA approval, retatrutide remains a trial-only option.

Side effects: what overlaps, what differs, and what’s “urgent”

Common side effects (all three)

Most patients report GI (gastrointestinal) side effects at some point, especially during dose increases:

nausea
diarrhea
constipation
vomiting
abdominal pain
indigestion / reflux
decreased appetite

Practical notes patients find helpful:

Side effects often peak after starting or increasing the dose, then improve.
Going up too fast can make side effects worse.
Dehydration is a common “hidden problem” when nausea/vomiting/diarrhea hit.

Internal link: GLP‑1 side effects: what to expect and when to call a doctor

Side effects and safety signals that may differ

These are not “you will have this,” but issues clinicians often consider in risk/benefit discussions:

Heart rate changes
- Retatrutide phase 2 research reported dose-dependent increases in heart rate that peaked around 24 weeks and declined thereafter.
- Semaglutide and tirzepatide can also increase heart rate in some patients, but the degree and frequency can vary.
Blood sugar lows (hypoglycemia)
- When used alone, these medicines generally have a low risk of hypoglycemia.
- Risk increases if combined with insulin or sulfonylureas.
- If you have diabetes, ask your clinician if other meds should be reduced when starting.
Gallbladder problems
- Rapid weight loss itself increases gallstone risk.
- GLP‑1–based drugs also have labeling warnings related to gallbladder disease.
- If you develop right-upper-abdominal pain, fever, or yellowing of skin/eyes, seek care.

“Stop waiting and call a clinician now” symptoms

If you’re taking (or considering) a GLP‑1–based medication and develop:

severe, persistent abdominal pain (especially with vomiting)
repeated vomiting with inability to keep fluids down
signs of dehydration (dizziness, fainting, very dark urine)
allergic reaction symptoms (swelling of face/lips/tongue, trouble breathing)

…contact urgent care/ER as appropriate.

Boxed warnings and contraindications (U.S. labeling context)

Semaglutide and tirzepatide: boxed warning about thyroid C‑cell tumors

FDA labels for Wegovy/Ozempic and Zepbound/Mounjaro include a boxed warning and contraindicate use in people with:

a personal or family history of medullary thyroid carcinoma (MTC), or
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

This is a key “yes/no” screening question in U.S. prescribing.

Retatrutide: what to know today

Because retatrutide is investigational, it does not have an FDA-approved prescribing label.

Clinical trials have inclusion/exclusion rules, safety monitoring, and reporting, but that is not the same as post-marketing safety data.
If you see retatrutide offered outside of a legitimate trial, treat that as a major red flag.

Cost and access in the U.S.: the practical reality

For many patients, the biggest difference isn’t biology—it’s access.

Retatrutide

Generally accessible only through clinical trials.
If you’re interested, ask your clinician about trial opportunities, or search ClinicalTrials.gov.

Semaglutide / tirzepatide

Coverage varies widely by employer plan, Marketplace plan, Medicaid rules, and medical indication.
Prior authorization is common.
Supply issues and dose availability can affect consistency.

Internal link: Compounded semaglutide/tirzepatide: what the FDA warns about

How to choose among them (a patient-centered checklist)

Bring these questions to your next appointment:

1) What is the goal?

weight management
type 2 diabetes management
cardiovascular risk reduction (if applicable)
another condition where weight loss is part of the plan

2) Are there any “hard stops” for safety?

Ask specifically about:

MTC/MEN2 history
pancreatitis history
gallbladder disease history
significant kidney disease or repeated dehydration
pregnancy plans (and what to do if pregnancy occurs)

3) What do you realistically have access to?

Which medication is covered?
What are your out-of-pocket costs?
Is it consistently in stock?

4) What’s your tolerability strategy?

Can you titrate slowly?
Do you have a nausea plan (food timing, hydration, clinician-approved meds if needed)?
When will you follow up if symptoms are severe?

5) What does “success” look like besides the scale?

Examples:

better blood pressure or cholesterol
improved mobility
improved sleep apnea symptoms
lower A1C (if you have diabetes)

FAQs

Is retatrutide “better” than semaglutide or tirzepatide?

Not enough information to say for an individual. Retatrutide has shown very large average weight loss in phase 2 research, but it is not FDA-approved and does not yet have the same level of long-term, real-world safety data as approved medications.

If tirzepatide averages more weight loss than semaglutide, should everyone switch?

No. Some people tolerate semaglutide better, have contraindications, or have better insurance coverage for one option. The “best” medication is often the one you can safely take, tolerate, and access consistently.

Are the side effects completely different?

No. They overlap heavily, especially GI side effects. Differences are usually about how intense side effects are for you, and how you respond during dose escalation.

Can I combine these medications?

Generally, combining GLP‑1–based incretin drugs is not standard practice and may increase side effects without proven benefit. Only do what your clinician prescribes.

References (U.S. and major medical sources)

Medical disclaimer

This content is for general educational purposes only and does not replace medical advice, diagnosis, or treatment from a licensed clinician. Do not start, stop, or change prescription medications without medical guidance. If you think you may have a medical emergency, call 911.